

#RESEARCHNEVERSTOPS

General company presentation



Evotec SE, Company presentation, August 2024

Disclaimer

This presentation (including any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further inquiries) is being delivered on behalf of Evotec SE (the "Company", "we," "our" or "us"). This presentation is made pursuant to Section 5(d) and/or Rule 163B of the Securities Act of 1933, as amended, and is intended solely for investors that are qualified institutional buyers or certain institutional accredited investors solely for the purposes of familiarizing such investors with the Company. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy Evotec securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No representations or warranties, express or implied, are made as to the accuracy or completeness of the statements, estimates, projections or assumptions contained in the presentation, and neither the Company nor any of its directors, officers, employees, affiliates, agents, advisors or representatives shall have any liability relating thereto.

Cautionary Note Regarding Forward-Looking Statements

This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Many of the forward-looking statements contained in this presentation can be identified by the use of forward-looking words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and other similar expressions that are predictions of or indicate future events and future trends, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors. The forward-looking statements contained in this presentation speak only as of the date of this presentation, and unless otherwise required by law, we do not undertake any obligation to update them in light of new information or future developments or to release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events.



- ¹ Together for Medicines that Matter
- ² Shared R&D
- ₃ Just Evotec Biologics
- 4 Financials





Accelerating medicines that matter

About us

4,000++ scientists empowering our partners

Across all disciplines and disease areas from target to commercial manufacturing

Co-creating pipelines

Leveraging our assets, targets or proprietary platforms for licensing, co-development or potential NewCo creation, frequently combining with Partners' programs, and ideas

R&D Biotech that offers accelerated, high-value pipeline co-creation, and R&D solutions

Performance – "Beyond FTEs"

Collaborating with "goal in mind", result-driven partnership models


Track record – highest quality, most capital-efficient execution

State-of-the-art services as core offering for partners



Leveraging the power of trust and collaboration in attractive markets

Sharing as basis for success





SCIENTIFIC EXCELLEN

INAL EXCELLENCE

Scientific AND operational excellence are both essential for our success

Benefits of increased emphasis on Operational excellence

Shared R&D – From target to patient

Discovery of next generation drugs with higher efficacy and probability of success. PanOmics approach for molecular disease understanding and iPSC disease modeling platform. In-vitro & in-silico prediction of human exposure, clinical efficacy and toxicological outcome. Design and execution of best strategies for rapid entry into first in human studies.

Just – Evotec Biologics – Global access to biotherapeutics

Design and application of innovative technologies from discovery to commercial supply to dramatically expand global access to biotherapeutics. Selecting best therapeutic candidate via A.I./M.L./ Automation. Implementation of "Lights-out" fully-continuous manufacturing. Reduction of environmental impact.





Shared R&D – Discovery of next generation drugs with higher efficacy and probability of success



Comprehensive integrated research and development

Illustrative functional capabilities of the End-to-End shared R&D continuum

 Disease area expertise Structural biology Exploratory biology Target validation Assay Development Structural biology Structural biology Screening, virtual screening Molecular optimisation PK/PD, ADME, PK Safety, biomarkers Safety, biomarkers Safety, biomarkers Safety, biomarkers Safety, biomarkers Safety, biomarkers Drug Product 	From Target				to Patient	
• Development	 Disease area expertise Exploratory biology Target validation Assay 	 Structural biology Screening, virtual screening Molecular design, 	 EVOgnostics Molecular optimisation PK/PD, ADME, PK Safety, 	 safety Formulation science Process development and 	 biology, biomarkers Clinical development support API manufacturing, product for clinical testing 	• Commercial API and drug product manufacturing

• Operational excellence and A.I./M.L.-driven predictive science

It all starts with precise patient data – From human to human


Portfolio of Evotec Molecular Patient Databases (E.MPD)





Paving the way towards increased clinical success

Overview of PanOmics drug discovery platform






Multiple options for pipeline co-creation together with our partners

>140 co-owned projects

	Neurosci	ence & pai	n		Oncology	,				Metaboli	c diseases			Inflamma Immunol		Virology,	Anti-bact	erial & Glo	bal health	1
Approved	Jingxin																			SK Bio
PhIII																				
PhII C linical					Carrick	Carrick	Carrick	Carrick		Sernova				Topas						
	Centrexion									Bayer					Topas					
PhI	BMS				Kazia		Exscientia	Immunitas						Conba	Exscientia					NIH
	ND	ND			ND	ND	EVT	EVT		ND	EVT	EVT								
	ND	ND			ND	ND	EVT	EVT		ND	EVT	EVT								
	ND	ND			ND	ND	EVT	EVT		ND	EVT	EVT			EVT					
	ND	ND			ND	ND	ND	EVT		ND	EVT	EVT			EVT				EVT	EVT
	ND	ND			ND	ND	ND	EVT		ND	EVT	EVT			EVT				EVT	EVT
Pre-clinical &	ND	ND			ND	ND	ND	EVT	EVT	ND	EVT	EVT			EVT				EVT	EVT
Discovery	ND	ND			ND	ND	ND	EVT	EVT	ND	EVT	EVT			EVT			ND	EVT	EVT
	ND	ND	ND	EVT	ND	ND	ND	EVT	EVT	ND	ND	EVT			EVT	ND	ND	ND	EVT	EVT
	ND	ND	ND	EVT	ND	ND	ND	EVT	EVT	ND	ND	EVT	EVT	ND	EVT	ND	ND	ND	EVT	EVT
	ND	ND	ND	EVT	ND	ND	ND	EVT	EVT	ND	ND	EVT	EVT	ND	EVT	ND	ND	ND	EVT	EVT
										>!	50									
										>1	20									
Partner	ed Pipelin	e U	Inpartner	ed Pipel	ine	Equity I	Pipeline	Brid	ges Pipel	line										
AGE 11			1 Also include	s Women's He	alth, Respirator	y projects														

1 Also includes Women's Health, Respiratory projects The Equity Pipeline does not contain programs from EVT/partners that are not publicly disclosed Status as of 31 December 2023






Just – Evotec Biologics Design and application of innovative technologies from discovery to commercial supply to dramatically expand global access to biotherapeutics

Paradigm shift in biologics




JUST is addressing global access by alleviating major pain points

Key advantages of biologics manufacturing with Just – Evotec Biologics



Time to set up facility, years



Proximity to key markets

J.POD[®] technology can be quickly established in other countries/regions




Just – Evotec Biologics carves the path for a **paradigm shift in biologics manufacturing** through its continuous manufacturing approach



New options to cure Rare Diseases


Underserved indications





Portfolio advancing towards clinical & commercial manufacturing


High level longitudinal portfolio overview: Just - Evotec Biologics





Our continuous platform will even further excel with complex biologics

Trends in global biologics pipelines




1 Innovative drugs only, excluding reformulations, biosimilars, diagnostics & imaging; snapshot as of June each year with missing phases not approximated; development status based on most progressed indication Source: Pharmaprojects Oct 2021; McKinsey analysis; interpolated data



Significant business expansion with commercial manufacturing

Closed Sales, in € m





Financials



Navigating in challenging markets

Condensed income statement 2023 – Evotec SE and subsidiaries

in € m ¹	2023	2022	Change	Comment
Revenues of which Just – Evotec Biologics (JEB)	7 81.4 108.4	7 51.4 51.3	4% >110%	 Cyber-related impact (especially Development and Cyprotex) Challenging markets (esp. biotech) Sandoz tech partnership
Gross margin Gross margin excl. JEB	22.6% 27.0%	23.2% <i>31.1%</i>	(60) base pts. (410) base pts.	Cyber, market, less MS, <i>Ramp-up of capacity at JEB</i>
Unpartnered R&D expense	64.8	70.2	(8)%	Investing into the future
Adjusted Group EBITDA ²	66.4	101.7	(34)%	Impacted by internal cyber-related costs
Adjusted Group EBITDA excl. JEB ²	72.4	138.3	(47)%	Majority of cyber-related costs accounted for within EVT Execute
Scope 1 & 2 emissions (tons CO ₂ e)	27,480	38,549	(29)%	Growing greener

1 Differences may occur due to rounding

2 Adjusted EBITDA excludes changes of contingent considerations, income from bargain purchase and impairments on goodwill, other intangible and tangible assets as well as the total non-operating result

	Guidance 2024¹	YE 2023	Comment
Group revenues	€ 790 - 820 m	€ 781.4 m	Strong growth of JEB; Soft market environment in Shared R&D
R&D expenditure ²	€ 50 - 60 m	€ 64.8 m	Focus on scalable first-in-class platforms and projects, safeguarding sustainable growth
Adjusted EBITDA ³	€ 15 - 35 m	€ 66.4 m	High fixed costs base; balancing efficiency measures with capacity needs for future growth



Three pillars towards profitable growth

Priority reset – Update (mid August 2024)

1 Portfolio adjustments

- Exit Gene Therapy
- Scale back API capacity
- Focused capital allocation to "right" R&D projects
- Ongoing strengthening of business development

2 Capacity & External spend

- First reduction in force concluded (100 roles); U.S. and UK done
- Social process ongoing in Germany, Italy and France
- Ongoing global purchasing optimisation programme with first initiatives implemented
- Relocation of projects


3 Footprint

- Site exits (Orth, Halle, & Marcy)
- Hamburg: MEC II – closure / transfer to other buildings completed
- Abingdon: B90 closure / transfer to B95 completed



Looking ahead

Strategic review & accelerated transformation underway (illustrative)





Financial calendar 2024

Commerzbank & ODDO BHF Corporate Conference 2023, Frankfurt/Main	03 September 2024
Morgan Stanley 21st Annual Global Healthcare Conference, New York	05 September 2024
Royal Bank of Canada CDMO Conference, virtual	23 September 2024
Berenberg Goldman Sachs 12th German Corporate Conference, Munich	24 September 2024
Jefferies Back to School fireside chat, virtual	11 October 2024
9M results 2024 & Capital Market Briefing	06 November 2024
German Equity Forum, Frankfurt/Main	25 November 2024



Appendix



Experienced management team with long-term mission

The management team



Experience

- 2017 2022 CEO of Mediq
- 2005 2017 Various leadership positions at Linde Group, since 2007 member of the Group Executive Committee & Head of Global Business Unit Healthcare
- 2000 2005 McKinsey & Company

Christian Wojczewski CEO (as of 1 July 2024)



Laetitia Rouxel CFO (since 2023)

Experience

- 2021-2023: Global CFO of Wavin
- 2018-2021: Divisional CFO, SVP M&A of Coty
- 1996-2018: Different finance functions & leadership roles at Pfizer, J&J and Danone

Matthias Evers

CBO (since 2022)

Experience

- 2002-2022: McKinsey & Company
- Significant exposure to the U.S., China, India, and Europe, where he supported R&D organisations to excel at innovation
- Areas of expertise: convergence of biology and technology
- Advisor and speaker at highprofile science events

Craig Johnstone COO (since 2019)

Experience

- 2012-2019: Various leadership roles at Evotec
- 1994-2012: Project, function, & leadership roles at AstraZeneca, Prosidion and Rapier Research
- Fellow of the Royal Society of Chemistry and Chartered Chemist, BSc in Chemistry and a PhD in organic and organometallic



Aurélie Dalbiez CPO (as of 15 June 2024)

Experience

- 2021 2024 Chief Human Resources Officer at Corbion
- Prior to Corbion, various leadership positions at Lonza AG and Novartis AG
- More than 25 years of experience in international HR leadership

Cord Dohrmann CSO (since 2010)

Experience

- 1999-2010: Leading DeveloGen from a start-up to an internationally recognised metabolic disease company
- 20 years in biomedical research at leading academic institutions and in the biotech industry





Global view and deep experience for best governance

Independent and diverse Supervisory Board



- Since 2014 Member of Evotec's Supervisory Board (2021 Chairperson)
- Since 2008, CMO of UCB S.A., Brussels (Belgium)
- 2001-2009, Member of the Executive Board of Schwarz Pharma AG, responsible for global R&D

Iris Löw-Friedrich CMO – UCB S.A.



Roland Sackers CFO & Managing Director QIAGEN N.V.

- Since 2019 Member of the Supervisory Board (2021 Vice Chair Person) and Chairman of the Audit Committee of Evotec
 Since 2004,
- CFO of QIAGEN N.V.
- 1999-2004, Auditor at Arthur Andersen

Camilla Macapili Languille • Head of Life Sciences Mubadala Investment Company

- Since 2022 Member of Evotec's Supervisory Board
- Since 2013, Different positions at Mubadala Investment Company, (UAE)
- 2011-2013, Senior Manager
 Mergers & Acquisitions Daiwa
 Capital Advisory Partners (France)
- 2007-2010: Investment Manager at Virgin Management Ltd. (UK)
- 2005-2007, Analyst at JPMorgan Securities, Inc. (UK/USA)



Duncan McHale Director of Weatherden Ltd.

- Since 2024 Member of Evotec's Supervisory Board
- Since 2017 Founder and Director of Weatherden Ltd.
- 2017-2023 CMO of Evelo
- 2011-2017 Vice President and Head Global Exploratory Development at UCB
- 2008-2011 AstraZeneca, most recent as Vice President Personalized Healthcare and Biomarkers
- 1999-2007 Pfizer, most recent position Executive Director



Wesley Wheeler Operating Advisor to KKR, Madison Dearborn Partners and Edgewater Capital

- Since 2024 Member of Evotec's Supervisory Board
- 2019-2023 President of UPS Healthcare
- 2011-2019 CEO & Director of Marken
- 2007-2010 CEO & Director of Patheon
- 2003-2007 President of Valeant Pharmaceuticals International
- 2002-2003 CEO of DSM Pharmaceuticals
- 1989-2002 SVP Manufacturing & Supply GlaxoSmithKline



- Since 2021 Member of Evotec's Supervisory Board
 Since 2020, Equity Partner et
- Since 2000, Equity Partner at Baker McKenzie
- Since 2017, Member of the Global Executive Committee of Baker McKenzie
- S4DX GmbH, Chair of the Advisory Committee


Constanze Ulmer-Eilfort Partner at Peters,

Schönberger & Partner



Sustainable growth enabled by commitment, culture, values & people

Sustainability at Evotec




1) These slides contain 2023 data.



Sustainability at Evotec


Selected ESG-KPIs





EVOequity portfolio making progress

Operational VC model – diversified portfolio with multiple shots on goal




- **Breakpoint Therapeutics** Nomination of first preclinical development candidate, BTX-011
- **Tubulis** Closing of upsized € 128 m Series B2 financing round
- **Carrick Therapeutics** First patient dosed in Phase 1b/2 clinical trial of Samuraciclib in combination with Vepdegestrant
- **Topas Therapeutics** Initiation of Phase 2a clinical trial for TPM502 in Celiac Disease
- **Tubulis** Strategic license agreement with Bristol Myers Squibb to develop next generation ADCs



Shareholders supporting sustainable growth

Shareholder structure¹





Volker Braun EVP Global Head of Investor Relations & ESG

+49 (0) 40 228 999 338 (direct) +49 (0) 151 1940 5058 (mobile) volker.braun@evotec.com